CTOs on the Move

Tmunity

www.tmunity.com

 
Our vision is to become the leading innovative global life-sciences company that unlocks the potential of T-cell biology and combines it with the power of T-cell engineering excellence to provide cures for patients. Through our model of seamless and rapid integration of research, translational medicine, manufacturing science, clinical development and customer-centric approaches, we will design and deliver enhanced state-of-the-art solutions for patients in a host of disease areas using Chimeric Antigen Receptors (CARs), Gene edited T-Cells, T regulatory cells (Treg), and engineered T Cell Receptors (TCRs)
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.tmunity.com
  • 3020 Market Street Suite 535
    Philadelphia, PA USA 19104
  • Phone: 215.966.1600

Executives

Name Title Contact Details
Jason Krentz
 Chief Technology Officer and Head of Technical Operations Profile

Funding

Tmunity raised $100M on 01/23/2018
Tmunity raised $35M on 04/19/2018
Tmunity raised $75M on 10/31/2019

Similar Companies

Alfa Wassermann

Alfa Wassermann, Inc. is a West Caldwell, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Symic Biomedical

Symic is developing a new category of therapeutics that offer an exciting and biologically innovative approach to treating disease. While it is clear that cells play an important role in tissue inflammation and regeneration, it is also known that the extracellular matrix (ECM) plays an equally critical role in maintaining healthy tissue. The ECM is the non-cellular component of the body’s tissues, and proteoglycans are important structural and functional macromolecules native to the ECM that are known to protect against tissue degradation and promote healing during illness or injury. Recognizing the importance of proteoglycans in many acute and chronic disease states, Symic developed a library of proprietary, ECM-specific compounds that mimic the protective effect of natural proteoglycans. For controlled injuries (e.g. incisions, balloon angioplasty), Symic’s ECM-specific compounds allow for local application, enhancing their ability to attenuate inflammation and reduce scarring only at the site of injury. In disease states known for chronic inflammation involving the ECM (e.g. cartilage in osteoarthritis), Symic’s technology can disrupt the cycle of degradation-inflammation by directly targeting and protecting the injured ECM. The ECM plays a critical role in many acute and chronic disease states, many of which have limited or no effective therapeutic options. Symic plans to advance its compounds in a variety of therapeutic areas with unmet clinical needs.

PAR Management

PAR Management is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carbon Sciences, Inc

Carbon Sciences Inc. is developing a breakthrough technology to transform carbon dioxide (CO2) emissions into the basic fuel building blocks required to produce gasoline, diesel fuel, jet fuel and other portable fuels.

Aspen Medical Products

Aspen Medical Products is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.